ak119 + cadonilimab

AK119 + cadonilimab is a combination of two monoclonal antibodies used in cancer immunotherapy research. **AK119** is a monoclonal antibody; specific target and details are not well-documented in current literature, but it is developed in the context of immuno-oncology. **Cadonilimab (AK104)** is a first-in-class tetravalent bispecific humanized IgG1 antibody targeting both the programmed cell death protein 1 (**PD-1**) and cytotoxic T-lymphocyte-associated protein 4 (**CTLA-4**) receptors. Cadonilimab functions as an immune checkpoint inhibitor, activating T cells and boosting anti-tumor immunity—its Fc-null design minimizes effector functions (ADCC, ADCP, CDC) and immune-related toxicities, and it is associated with higher drug retention within the tumor microenvironment. Cadonilimab is approved for recurrent or metastatic cervical cancer and is under investigation for other cancer types, including gastric, hepatocellular, and head and neck cancers. Combination regimens of AK119 + cadonilimab are being explored in clinical trials, especially for advanced and hard-to-treat cancers.

Brand names

Cadonilimab (for AK104)Atyrso (for AK104)

Other names

ak119 + ak104